Danuglipron vs Semaglutide
How Danuglipron and Semaglutide compare — what each is, how strong the human evidence is for each, doses reported in research, the key risks, and 2026 US legal status. No universal winner.
Danuglipron and Semaglutide come up together when people are weighing similar options. Here's the honest side-by-side: what each is, how strong the human evidence is for each, the doses reported in research, the risks, and where each stands with the FDA as of 2026. There's no universal winner — scroll to the by-goal picks for which one fits which goal.
Danuglipron vs Semaglutide, point by point
Every dimension side by side — the honest differences, not a scoreboard.
| Dimension | Danuglipron | Semaglutide |
|---|---|---|
| What it is | Non-peptide small-molecule GLP-1 receptor agonist (an oral drug, not a peptide) | GLP-1 receptor agonist (a synthetic analog of the human gut hormone glucagon-like peptide-1) |
| Class / category | Incretin / metabolic | Incretin / metabolic |
| Evidence tier | Human RCT · Mixed | Human RCT · Helped |
| Studied / approved for | Type 2 diabetes; Chronic weight management | Type 2 diabetes (blood-sugar control); Chronic weight management in obesity or overweight; Cardiovascular risk reduction |
| US regulatory status (2026) | withdrawn (as of Jul 2026) | fda approved (as of Jul 2026) — approved for Type 2 diabetes (Ozempic, Rybelsus), Chronic weight management (Wegovy), Cardiovascular risk reduction |
| Doses reported in research | No established study doses | No established study doses |
| Registered trials (ClinicalTrials.gov) | No data | 716 |
| Banned in sport (WADA) | Yes — on the WADA prohibited list | No |
| Key risks | Danuglipron produced the expected GLP-1 gastrointestinal adverse events, with high discontinuation rates in the obesity trial. Pfizer reported that liver enzyme elevations across more than 1,400 participants were in line with approved drugs in the class, but one asymptomatic potential drug-induced liver injury resolved after stopping treatment and led Pfizer to end development. | Semaglutide is one of the most-studied peptides in humans, so its risks are well characterized rather than guessed at. The common side effects are gastrointestinal — nausea, vomiting, diarrhea, constipation — usually worst during dose increases. Less common but serious concerns include pancreatitis and gallbladder disease, and the label carries a boxed warning about thyroid C-cell tumors seen in rodents, which is why it is contraindicated in people with a personal or family history of medullary thyroid cancer or MEN 2. |
- Evidence tier: A tier reflects how human the evidence is, not a promise the compound works.
Danuglipron vs Semaglutide: the two molecules
The 2D chemical structures, straight from PubChem — a quick way to see how similar (or not) the two actually are.
Which one fits which goal?
There's no universal winner here — the honest answer depends on what you're after. These picks are framed by goal, and each says why.
If you want an FDA-approved, prescribable option
Leans toward Semaglutide
Semaglutide is FDA-approved (as of Jul 2026); Danuglipron is withdrawn in the US, so it isn't available as an approved prescription.